Inhibition of Plasmodium falciparum Growth In Vitro and Adhesion to Chondroitin-4-Sulfate by the Heparan Sulfate Mimetic PI-88 and Other Sulfated Oligosaccharides

ABSTRACT A panel of sulfated oligosaccharides was tested for antimalarial activity and inhibition of adhesion to the placental malaria receptor chondroitin-4-sulfate (CSA). The heparan sulfate mimetic PI-88, currently undergoing phase II anticancer trials, displayed the greatest in vitro antimalarial activity against Plasmodium falciparum (50% inhibitory concentration of 7.4 μM) and demonstrated modest adhesion inhibition to cell surface CSA.

[1]  Levon M Khachigian,et al.  Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. , 2006, Cardiovascular drug reviews.

[2]  Vito Ferro,et al.  Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). , 2005, Journal of medicinal chemistry.

[3]  K. Andrews,et al.  Carrageenans inhibit the in vitro growth of Plasmodium falciparum and cytoadhesion to CD36 , 2005, Parasitology Research.

[4]  K. Andrews,et al.  Inhibition of Chondroitin-4-Sulfate-Specific Adhesion of Plasmodium falciparum-Infected Erythrocytes by Sulfated Polysaccharides , 2005, Infection and Immunity.

[5]  S. Krudsood,et al.  Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[6]  K. Kain,et al.  Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes , 2003, The Lancet.

[7]  G. McArthur,et al.  Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Fairlie,et al.  Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. , 2000, International journal for parasitology.

[9]  M. Molyneux,et al.  Cytoadherence characteristics of Plasmodium falciparum-infected erythrocytes from Malawian children with severe and uncomplicated malaria. , 1999, The American journal of tropical medicine and hygiene.

[10]  W. Cowden,et al.  Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. , 1999, Cancer research.

[11]  M. Wahlgren,et al.  Plasmodium falciparum: molecular background to strain-specific rosette disruption by glycosaminoglycans and sulfated glycoconjugates. , 1999, Experimental parasitology.

[12]  A. M. Lawson,et al.  Inhibition of Binding of Malaria-Infected Erythrocytes by a Tetradecasaccharide Fraction from Chondroitin Sulfate A , 1998, Infection and Immunity.

[13]  A. Sahlén,et al.  Identification of Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1) as the Rosetting Ligand of the Malaria Parasite P. falciparum , 1998, The Journal of experimental medicine.

[14]  E. Davidson,et al.  Saccharide anions as inhibitors of the malaria parasite , 1997, Glycoconjugate Journal.

[15]  Patrick E. Duffy,et al.  Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta , 1996, Science.

[16]  V. Udhayakumar,et al.  Sulfated polyanions inhibit invasion of erythrocytes by plasmodial merozoites and cytoadherence of endothelial cells to parasitized erythrocytes , 1996, Infection and immunity.

[17]  C. Newbold,et al.  Plasmodium falciparum: a family of sulphated glycoconjugates disrupts erythrocyte rosettes. , 1994, Experimental parasitology.

[18]  M. Wahlgren,et al.  Plasmodium falciparum erythrocyte rosetting is mediated by promiscuous lectin-like interactions , 1992, The Journal of experimental medicine.

[19]  M. Wahlgren,et al.  Disruption of Plasmodium falciparum erythrocyte rosettes by standard heparin and heparin devoid of anticoagulant activity. , 1992, The American journal of tropical medicine and hygiene.

[20]  T. Solomon,et al.  Cerebral malaria in children , 1990, The Lancet.

[21]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[22]  K. Kain,et al.  Peroxisome Proliferator-Activated Receptorg-Retinoid X Receptor Agonists Increase CD36-Dependent Phagocytosis of Plasmodium falciparum-Parasitized Erythrocytes and Decrease Malaria-Induced TNF-a Secretion by Monocytes/Macrophages , 2001 .

[23]  M. Molyneux,et al.  Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria , 2000, Nature Medicine.

[24]  T. H. Rampengan.  Cerebral malaria in children. Comparative study between heparin, dexamethasone and placebo. , 1991, Paediatrica Indonesiana.

[25]  M. Munir,et al.  Heparin in the treatment of cerebral malaria. , 2021, Paediatrica Indonesiana.